Cite
Wnt pathway antagonists, SFRP1, SFRP2, SOX17, and PPP2R2B, are methylated in gliomas and SFRP1 methylation predicts shorter survival.
MLA
Majchrzak-Celińska, Aleksandra, et al. “Wnt Pathway Antagonists, SFRP1, SFRP2, SOX17, and PPP2R2B, Are Methylated in Gliomas and SFRP1 Methylation Predicts Shorter Survival.” Journal of Applied Genetics, vol. 57, no. 2, May 2016, pp. 189–97. EBSCOhost, https://doi.org/10.1007/s13353-015-0312-7.
APA
Majchrzak-Celińska, A., Słocińska, M., Barciszewska, A.-M., Nowak, S., & Baer-Dubowska, W. (2016). Wnt pathway antagonists, SFRP1, SFRP2, SOX17, and PPP2R2B, are methylated in gliomas and SFRP1 methylation predicts shorter survival. Journal of Applied Genetics, 57(2), 189–197. https://doi.org/10.1007/s13353-015-0312-7
Chicago
Majchrzak-Celińska, Aleksandra, Marta Słocińska, Anna-Maria Barciszewska, Stanisław Nowak, and Wanda Baer-Dubowska. 2016. “Wnt Pathway Antagonists, SFRP1, SFRP2, SOX17, and PPP2R2B, Are Methylated in Gliomas and SFRP1 Methylation Predicts Shorter Survival.” Journal of Applied Genetics 57 (2): 189–97. doi:10.1007/s13353-015-0312-7.